Back to Search
Start Over
WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases
- Source :
- Microbiology and immunology. 48(3)
- Publication Year :
- 2004
-
Abstract
- The Wilms' tumor gene WT1 is overexpressed in various types of solid tumors, including lung and breast cancer and WT1 protein is a tumor antigen for these malignancies. In phase I clinical trials of WT1 peptide-based cancer immunotherapy, two patients with advanced lung cancer were intradermally injected with 0.3 mg of an HLA-A*2402-restricted, 9-mer WT1 peptide emulsified with Montanide ISA51 adjuvant. Consecutive WT1 vaccination at 2-week intervals resulted in a reduction in tumor markers such as chorio-embryonic antigen (CEA) and sialyl Lewis (x) (SLX) and by a transient decrease in tumor size. No adverse effects except for local erythema at the injection sites of WT1 vaccine were observed. These results provided us with the first clinical evidence demonstrating that WT1 peptide-based immunotherapy should be a promising treatment for patients with lung cancer.
- Subjects :
- Oncology
Male
congenital, hereditary, and neonatal diseases and abnormalities
medicine.medical_specialty
Lung Neoplasms
medicine.medical_treatment
Immunology
Biology
urologic and male genital diseases
Microbiology
Cancer Vaccines
Breast cancer
Drug Delivery Systems
Cancer immunotherapy
Antigen
Antigens, Neoplasm
Virology
Internal medicine
medicine
Humans
Lung cancer
WT1 Proteins
Aged
HLA-A Antigens
urogenital system
fungi
Cancer
Immunotherapy
Middle Aged
medicine.disease
female genital diseases and pregnancy complications
Tumor antigen
Peptide Fragments
Treatment Outcome
Cancer research
Female
Adjuvant
Subjects
Details
- ISSN :
- 03855600
- Volume :
- 48
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- Microbiology and immunology
- Accession number :
- edsair.doi.dedup.....4b0cdd40c0721415636f8c5a5ba98e3d